EMEA To Get To Heart Of COX-2 Inhibitor Safety Issues At Feb. 14-17 Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The Committee for Medicinal Products for Human Use requests further analyses from Pfizer, Merck and Novartis on the cardiovascular safety of COX-2 inhibitors. Pfizer agrees not to launch celecoxib for in an orphan polyp indication until after completion of EMEA's class safety review.
You may also be interested in...
Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007
Prexige is approved in EU and Canada for osteoarthritis symptoms, company announces.
Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007
Prexige is approved in EU and Canada for osteoarthritis symptoms, company announces.
COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda
FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.